| |
Transperineal biopsy (N = 92)
|
Transrectal biopsy (N = 85)
|
p
|
|---|
|
Total number of targets
|
104
|
92
| |
|
Age
|
66 (61–72)
|
67 (62–73)
|
0.61
|
|
DRE, n (%)
| | |
0.312
|
|
Negative
|
65 (70.6%)
|
62 (72.9%)
| |
|
Positive
|
27 (29.3%)
|
23 (27.0%)
| |
|
Previous biopsy, n (%)
| | |
0.844
|
|
Biopsy naïve
|
64 (69.5%)
|
57 (67.0%)
| |
|
Repeat biopsy
|
28 (30.4%)
|
28 (32.9%)
| |
|
PSA, ng/mL
|
7.5 (5.30–13.28)
|
8.04 (5.76–12.12)
|
0.608
|
|
Prostate volume, ml
|
42.34 (29.93–59.08)
|
43.4 (30.9–54.9)
|
0.582
|
|
PSAD
|
0.18 (0.11–0.32)
|
0.18 (0.12–0.27)
|
0.729
|
|
PI-RAS score, n (%)
| | |
0.277
|
|
3
|
19 (18.2%)
|
13 (14.1%)
| |
|
4
|
48 (46.1%)
|
53 (57.6%)
| |
|
5
|
37 (35.5%)
|
26 (28.2%)
| |
|
Total core number, n
|
26 (23–28)
|
20 (16–22)
|
< 0.001
|
|
Targeted biopsy
|
6 (4–7)
|
4 (3–4)
|
< 0.001
|
|
Systematic biopsy
|
19 (17–22)
|
16 (12–18)
|
< 0.001
|
|
Target lesion size, mm
|
12 (9–19.25)
|
10.5 (6.75–16)
|
0.305
|
|
Target lesion location, n (%)
| | | |
|
Anterior
|
41 (39.4%)
|
31 (33.6%)
|
0.406
|
|
posterior
|
63 (60.5%)
|
61 (66.3%)
| |
- Continuous data were show as median (IQR)
- DRE, digital rectal exam; IQR, interquadrant range; PSA, prostate specific antigen; PSAD, prostate specific antigen density; PI-RADS, Prostate Imaging Reporting & Data System
